ACCELERATING LIFE SCIENCE INNOVATION
Paragon solves complex human and societal challenges by creating and supporting focused, visionary companies that accelerate development of novel therapies and life science breakthroughs.
ACCELERATING LIFE SCIENCE INNOVATION
Paragon solves complex human and societal challenges by creating and supporting focused, visionary companies that accelerate development of novel therapies and life science breakthroughs.
ACCELERATING LIFE SCIENCE INNOVATION
Paragon solves complex human and societal challenges by creating and supporting focused, visionary companies that accelerate development of novel therapies and life science breakthroughs.
“Challenges which others have deemed unsolvable are the problems we are solving.”
~ Jeffrey S. Aronin
Paragon founder, chairman and CEO
Portfolio
Since 2017, Paragon has successfully launched seven portfolio companies, including a recent upsized IPO, while maintaining a consistent flow of companies in development.
Leveraging its proprietary fibroblast technology platform to expand an innovative gene therapy pipeline, developing personalized treatments for underserved disorders, including epidermolysis bullosa and localized scleroderma.
Concentrating on cell therapy treatments for serious diseases with high, unmet needs with an initial focus on the eye, including geographic atrophy age-related macular degeneration and advanced retinitis pigmentosa.
Creating treatments for central nervous system movement disorders and fluency disorders, including Tourette syndrome and childhood-onset fluency disorder (stuttering) in adults.
Evozyne is combining the exquisite complexity of nature with advanced machine learning to create novel proteins with extraordinary impact across a variety of industries.
Commercializing biopharmaceutical treatment options for people living with rare diseases, including disorders of sleep and wakefulness, such as narcolepsy, Prader-Willi syndrome and myotonic dystrophy.
Assisting radiologists to significantly improve clinical assessment and characterization of cancerous breast abnormalities through artificial intelligence-driven technology that enhances clinical insights.
News
Paragon Biosciences Appoints Jordan Dubow as Chief Medical Officer
Chicago, February 23, 2021—With continued growth in its portfolio of life science companies, Paragon Biosciences announced the appointment of Jordan Dubow, M.D., as chief medical officer. Dr. Dubow is responsible [...]
Paragon Biosciences Launches CiRC Biosciences to Expand Cell and Gene Therapy Platform
Its vision restoration technology featured in Nature and New England Journal of Medicine; CiRC is Paragon’s 7 th portfolio company, with more in development Chicago, February 2, 2021 – Paragon Biosciences, a [...]
First Patient Dosed in Emalex Biosciences Phase 2 Clinical Trial for Stuttering
Chicago – December 15, 2020 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders, announced that the first adult patient [...]
Paragon Biosciences Appoints Jordan Dubow as Chief Medical Officer
Chicago, February 23, 2021—With continued growth in its portfolio of life science companies, Paragon Biosciences announced the appointment of Jordan Dubow, M.D., [...]
Paragon Biosciences Launches CiRC Biosciences to Expand Cell and Gene Therapy Platform
Its vision restoration technology featured in Nature and New England Journal of Medicine; CiRC is Paragon’s 7 th portfolio company, with more in development [...]
First Patient Dosed in Emalex Biosciences Phase 2 Clinical Trial for Stuttering
Chicago – December 15, 2020 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and [...]
Paragon Biosciences Appoints Jordan Dubow as Chief Medical Officer
Chicago, February 23, 2021—With continued growth in its portfolio of life science companies, Paragon Biosciences announced the appointment of Jordan Dubow, M.D., [...]
Paragon Biosciences Launches CiRC Biosciences to Expand Cell and Gene Therapy Platform
Its vision restoration technology featured in Nature and New England Journal of Medicine; CiRC is Paragon’s 7 th portfolio company, with more in development [...]
First Patient Dosed in Emalex Biosciences Phase 2 Clinical Trial for Stuttering
Chicago – December 15, 2020 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and [...]
